Skip to main content

Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)

Buy Article:

$68.00 + tax (Refund Policy)

The central nervous system (CNS) barriers are composed of blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (B-CSFB). The BBB and B-CSFB are a highly specialized brain endothelial and epithelial structure of the fully differentiated neurovascular system. These barriers separate components of the circulating blood from neurons. Moreover, the BBB and B-CSFB maintain the chemical composition of the neuronal “milieu,” which is required for the proper functioning of neuronal circuits, synaptic transmission, synaptic remodelling, angiogenesis, and neurogenesis in the adult brain. Hematoencephalic barrier breakdown, due to disruption of the tight junctions, alters transport of molecules between blood and brain and vice versa, causes an aberrant angiogenesis, vessel regression, and inflammatory responses. Megalin is a multi-ligand endocytic receptor expressed in the choroid plexus epithelium and in the brain-endothelial cells, playing a central role in the clearance/entrance of many proteins from the brain or cerebrospinal fluid (CSF). Megalin cooperates with various membrane molecules and interacts with many adaptor proteins for endocytic trafficking. It has already been implicated in amyloid-β clearance and amyloidosis through the BBB and B-CSFB. Also, it is a promiscuous receptor involved in the endocytic uptake of many ligands, including many of the known carriers of amyloid-β, insulin, IGF-I, leptin, transthyretin, transferrin, ApoE and others. The knowledge of B-CSFB and its transporters in healthy and pathological situations supports the development of new therapeutic approaches for chronic diseases such as Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, multiple sclerosis, brain cancer, diabetes and others. This article outlines recent patents on artificial carriers for transport of substances across of the CNS barriers, different models for the drug delivery research and future therapies for the treatment of Alzheimer's disease.





Keywords: (Dab)-1; Alzheimer's disease; Amyloid; Apolipoprotein E receptors type-2; Dab2; FXNPXY sequences; IGF; LDL-R-related protein 1; LRP-1; LRP-2; MCTF; Notch; Regulated Intramembrane Proteolysis; amyloidosis; apical surface; arachnoid epithelium; astrocytes; autosomal recessive hypercholesterolemia; blood-CSF barrier; blood-brain barrier; c-Jun N-terminal kinase -interacting protein; cerebrovascular endothelial cells; choroid plexus epithelial cells; choroid plexus epithelium; cingulin; clathrin-coated pits; claudins; clearance; disabled homolog; drug delivery; intracellular domain; kinase scaffold proteins; megalin; membrane-associated C-terminal fragment; metallo-proteinase; milieu; mitogen-activating protein; occludins; p75NTR signalling pathway; pericytes; pino-cytic vesicles; presenilin 1; regulated intramembrane proteolysis; semaphorin-binding protein-1; synaptic density protein-95; transthyretin; very low-density lipoprotein receptor

Document Type: Research Article

Publication date: 01 November 2010

More about this publication?
  • Recent Patents on Endocrine, Metabolic & Immune Drug Discovery publishes review articles by experts on recent patents in the field of endocrine, metabolic and immune drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in endocrine, metabolic and immune drug design and discovery.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content